Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial

Sun Young Rha; Toni K. Choueiri; Vsevolod B. Matveev; Anna Alyasova; Sung-Hoo Hong; Teresa Alonso Gordoa; Howard Gurney; Georg A. Bjarnason; Tomas Buchler; Paolo Pedrazzoli; Toshio Takagi; Se Hoon Park; Jae-Lyun Lee; Rodolfo F. Perini; Cixin He; Jodi A. McKenzie; Masatoshi Eto

doi:10.1200/JCO.2022.40.6_suppl.338

YUHSpace

BROWSE

0 267

Cited 0 times in

Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial

Authors: Sun Young Rha ; Toni K. Choueiri ; Vsevolod B. Matveev ; Anna Alyasova ; Sung-Hoo Hong ; Teresa Alonso Gordoa ; Howard Gurney ; Georg A. Bjarnason ; Tomas Buchler ; Paolo Pedrazzoli ; Toshio Takagi ; Se Hoon Park ; Jae-Lyun Lee ; Rodolfo F. Perini ; Cixin He ; Jodi A. McKenzie ; Masatoshi Eto